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What is Already Known about this Subject {#bcp13846-sec-0005}
========================================

Therapeutic targets for plasma concentration of isoniazid and rifampicin are already known in the treatment of tuberculosis.Exposure to antituberculosis drugs is generally known to be lower in children compared to the therapeutic targets using standard dosing regimens.

What this Study Adds {#bcp13846-sec-0007}
====================

This study demonstrates that the exposure of isoniazid is adequate while that of rifampicin is inadequate using standard dosing regimens.The pharmacometric analysis of data presented here, suggests that a dose of 35 mg kg^--1^ is required to achieve adequate peak concentrations of rifampicin in most children.

Introduction {#bcp13846-sec-0008}
============

Tuberculosis is a global health problem, with an estimated annual global incidence of 10.4 million cases in 2016. With an annual incidence of 2.79 million cases, India accounts for 25% of the total global burden and has been found to have the largest number of cases per country [1](#bcp13846-bib-0001){ref-type="ref"}. Of these, 230 000 cases were in children younger than 14 years [1](#bcp13846-bib-0001){ref-type="ref"}. Disease burden in children is likely to be underestimated due to difficulties in accurate diagnosis, as paediatric pulmonary tuberculosis is most often smear‐negative and culture confirmation is not widely available in resource‐poor settings [2](#bcp13846-bib-0002){ref-type="ref"}.

The standard treatment regimens of tuberculosis have minor variations in drug doses between the recommendations from the World Health Organization (WHO) and those of various national health programmes. The total duration of therapy includes 2 months of an intensive phase followed by 4 months of a maintenance phase in most regimens. Isoniazid and rifampicin are the two first‐line drugs used in the treatment of tuberculosis throughout the treatment period, with additional pyrazinamide and ethambutol given in the initial intensive phase [3](#bcp13846-bib-0003){ref-type="ref"}.

The Revised National Tuberculosis Control Programme (RNTCP) in India has provided free treatment since 1993, as directly observed treatment short course (Regimen 1 in Table [1](#bcp13846-tbl-0001){ref-type="table"}). The initial regimen was changed in 2012 (Regimen 2, Table [1](#bcp13846-tbl-0001){ref-type="table"}) to follow the WHO Rapid Advice from 2010 [4](#bcp13846-bib-0004){ref-type="ref"}. With the trend shifting to fixed‐dose combinations (FDC) in the treatment of tuberculosis, a newer FDC‐based regimen is being implemented (Regimen 3, Table [1](#bcp13846-tbl-0001){ref-type="table"}) [5](#bcp13846-bib-0005){ref-type="ref"}. Regimen 3 is a daily regimen with different doses of isoniazid (7.1--12.5 mg kg^--1^) and rifampicin (10.7--18.8 mg kg^--1^), which is closer to the currently recommended dosing by WHO [6](#bcp13846-bib-0006){ref-type="ref"}. Although the national programme follows a unified approach to therapy, the choice of the regimen in the private sector is often based on the clinician\'s discretion.

###### 

Regimens in the treatment of tuberculosis

  Regimen 1        Regimen 2         Regimen 3   Regimen 4                                                  
  ---------------- ----------------- ----------- --------------------- -------- ------------------ -------- -----------------------------
  **Isoniazid**                                                                                             
  **6--10**        75 (12.5--7.5)    6--7        75 (12.5--10.7)       4--7     50 (12.5--7.14)             
  **11--17**       150 (13.6--8.8)   8--11       112.5 (14.06--10.2)   8--11    100 (12.5--9.1)             
  **18--25**       225 (12.5--9)     12--15      150 (12.5--10)        12--15   150 (12.5--10)              
  **26--30**       300 (11.5--10)    16--17      187.5 (11.7--11.1)    16--24   200 (12.5--8.3)             
                                     18--22      225 (12.5--10.2)      25--29   225 (9--7.7)                
                                     23--30      300 (13.6--10)        30--39   250 (8.3--6.4)              
  **Rifampicin**                                                                                            
  **6--10**        75 (12.5--7.5)    6--7        75 (12.5--10.7)       4--7     75 (18.7--10.7)    6--11    35 mg kg^--1a^ (suspension)
  **11--17**       150 (13.6--8.8)   8--11       112.5 (14.06--10.2)   8--11    150 (18.7--13.6)   12--14   450 (37.5--32.1)
  **18--25**       225 (12.5--9)     12--15      150 (12.5--10)        12--15   225 (18.7--15)     15--19   600 (31.5--40)
  **26--30**       300 (11.5--10)    16--17      187.5 (11.7--11.1)    16--24   300 (18.7--12.5)   20--23   750 (37.5--32.6)
                                     18--22      225 (12.5--10.2)      25--29   375 (15--12.9)     24--27   900 (37.5--33.3)
                                     23--30      300 (13.6--10)        30--39   450 (15--11.5)     28--30   1050(37.5--35)

Regimen 1 is a thrice‐weekly regimen. Regimen 2 is given as either daily (World Health Organization recommended) or thrice weekly (earlier recommendation by Revised National Tuberculosis Control Programme). However, the dose given at an occasion in both daily and thrice‐weekly regimen are the same. Regimen 3 is an fixed‐dose combination‐based daily regimen

In the proposed regimen 4, an average dose of 35 mg kg^--1^ body weight was maintained in all weight bands using the already available tablet strengths. A high dose of 35 mg kg^--1^ was easily accessible for younger children (6--11 kg) by using an already available suspension formulation (^a^) of the drug

Even with improvements in the dosing regimen, pharmacokinetic studies have shown that the currently recommended dosage regimens result in inadequate drug levels in children aged 2 months to 12 years [7](#bcp13846-bib-0007){ref-type="ref"}, [8](#bcp13846-bib-0008){ref-type="ref"}, [9](#bcp13846-bib-0009){ref-type="ref"}. Similar results have also been observed with earlier regimens in studies from India [10](#bcp13846-bib-0010){ref-type="ref"}, [11](#bcp13846-bib-0011){ref-type="ref"}. Suboptimal blood levels could lead to treatment failure and the emergence of drug resistance [2](#bcp13846-bib-0002){ref-type="ref"}. This emphasizes the need for further pharmacokinetic studies from which new dose regimens can be proposed.

The pharmacokinetics of isoniazid and rifampicin are complex due to their unique properties. Isoniazid metabolism is dependent on the genotype of the N‐acetyl transferase enzyme, which explains the large variability in its clearance [8](#bcp13846-bib-0008){ref-type="ref"}. Rifampicin induces multiple cytochrome P450 enzymes and glucuronidation enzymes, including those responsible for its own metabolism, causing metabolic autoinduction of rifampicin, which might lead to drug interactions when combined with other drugs [9](#bcp13846-bib-0009){ref-type="ref"}. The clinical efficacy of these drugs is known to correlate with the concentration attained in the patient [12](#bcp13846-bib-0012){ref-type="ref"}. For example, a peak isoniazid concentration (C~max~) of \<3 μg ml^--1^ after a daily regimen, or \<9 μg ml^--1^ after a twice‐weekly regimen are considered ineffective [12](#bcp13846-bib-0012){ref-type="ref"}. There are no well‐defined optimal plasma concentrations available for thrice‐weekly therapy. However, a study performed in children found a trend to unfavourable outcomes associated with peak concentrations \<6 μg ml^--1^, which can therefore, be considered a cut‐off for clinical efficacy in the absence of more evidence [13](#bcp13846-bib-0013){ref-type="ref"}. Also for isoniazid, based on *in vitro* studies and *in vivo* studies, a minimum exposure after one dose (AUC~0--24\ h\ after\ dose~) of 10.52 μg × h ml^--1^ is considered adequate in terms of early bactericidal activity and therefore a marker for clinical efficacy [14](#bcp13846-bib-0014){ref-type="ref"}, [15](#bcp13846-bib-0015){ref-type="ref"}. For rifampicin, a peak concentration of 8--24 μg ml^--1^ is considered optimal for good clinical efficacy, and concentrations \<8 μg ml^--1^ and \<4 μg ml^--1^ are considered low and very low, respectively [12](#bcp13846-bib-0012){ref-type="ref"}.

The aim of this study was to investigate the pharmacokinetic properties of isoniazid and rifampicin in children in southern India and to evaluate the exposure associated with the dose regimens of these drugs in the current study.

Methods {#bcp13846-sec-0009}
=======

Study design {#bcp13846-sec-0010}
------------

The present study was conducted at the Clinical Pharmacology Unit and the Departments of Paediatrics and Community Health at Christian Medical College, Vellore, Tamil Nadu, India. The overall clinical efficacy and safety results from this study have been published previously [10](#bcp13846-bib-0010){ref-type="ref"}. Children and adolescents aged 2--16 years (hereafter referred to as children) who were newly diagnosed with pulmonary or lymph node tuberculosis with a minimum blood haemoglobin of 10 g dl^--1^ were recruited (demographic characteristics in Table [2](#bcp13846-tbl-0002){ref-type="table"}). Children with disease relapse, multidrug resistant tuberculosis and co‐existing human immunodeficiency infection were excluded from the study. Isoniazid and rifampicin were given along with pyrazinamide and ethambutol to all the children in the intensive phase (first 8 weeks) of therapy either thrice weekly or daily. All the children received isoniazid and rifampicin for a minimum period of 6 months. The pharmacokinetic samples were collected during the last 2 weeks of the intensive therapy, ensuring that steady‐state levels had been achieved [9](#bcp13846-bib-0009){ref-type="ref"}.

###### 

Demographics characteristics of the enrolled study children (*n =* 41)

  Characteristic                Value
  ----------------------------- ------------------------
  **Age (years)**               7 (3.5--13)
  **Sex (male/female)**         29/12
  **Body weight (kg)**          19.5 (13.7--33.7)
  **Height (cm)**               118 (97--154)
  **Body mass index**           14.8 (13.9--15.6)
  **Z score**                   −1.22 (−2.41 to −0.74)
  **Diagnosis**                 
  **Pulmonary tuberculosis**    36
  **Lymph node tuberculosis**   5

All results are expressed as median (interquartile range) unless otherwise specified

The Department of Paediatrics prescribed the daily WHO regimen as unobserved treatment [4](#bcp13846-bib-0004){ref-type="ref"}, while the children from the peripheral care centre of the Department of Community Health were prescribed the thrice‐weekly directly observed treatment according to the RNTCP recommendation [16](#bcp13846-bib-0016){ref-type="ref"}. Both regimens are similar in terms of the actual dose given in a day but differ with regards to the frequency i.e. either daily or thrice weekly. Target dosage (mg kg^--1^ dose) is available in Table [1](#bcp13846-tbl-0001){ref-type="table"} (Regimen 2). On the day of sampling, participating children were kept fasting (overnight) with no restriction on water. Ethical approval for the study was given by the Institutional Review Board (IRB Min No. 8892, Christian Medical College, Vellore). The study was explained in their own language and informed consent was obtained from the parents or guardians, and whenever possible, consent was also taken from the child. All procedures were performed according to the revised version of the Declaration of Helsinki.

Specimen collection and analytical methods {#bcp13846-sec-0011}
------------------------------------------

Information on age, sex, body mass index, weight and comedication history was recorded for all the children during the initial visit and on the day of pharmacokinetic study. On the day of the study, blood samples were collected before dose administration (trough concentration) and at 0.5, 1, 1.5, 2, 2.5, 4 and 6 h post‐dose. The samples were collected in EDTA‐containing vacutainers and were transported to the laboratory in a Styrofoam box filled with ice packs. The plasma was then immediately separated by centrifugation. Isoniazid concentration measurement was performed within 5 h from the time of collection using a validated LC--MS/MS. Rifampicin was measured using a validated HPLC‐UV assay within 72 h of collection. The validation of these assays has been described previously [10](#bcp13846-bib-0010){ref-type="ref"}. The lower limit of quantification (LLOQ) for isoniazid and rifampicin were 0.01 μg ml^--1^ and 0.04 μg ml^--1^, respectively. The precision (coefficient of variation) of the isoniazid assay was 6.25% and 1.70% for concentrations 0.1 μg ml^--1^ and 10 μg ml^--1^, respectively. The precision of the rifampicin assay was 3.95% and 1.62% for concentrations of 0.24 μg ml^--1^ and 10 μg ml^--1^, respectively.

Population pharmacokinetic modelling {#bcp13846-sec-0012}
------------------------------------

Isoniazid and rifampicin concentration--time data were characterized separately using nonlinear mixed‐effects modelling, in the software NONMEM 7.3. The first‐order conditional estimation method with η--ε interaction (FOCE‐I) was used throughout modelling. The pharmacokinetic parameters were estimated using the natural‐log transformed plasma concentrations [17](#bcp13846-bib-0017){ref-type="ref"}, [18](#bcp13846-bib-0018){ref-type="ref"}. Perl‐Speaks‐NONMEM v.4.6.0 [19](#bcp13846-bib-0019){ref-type="ref"}, R v.3.3.0 (R Foundation for Statistical Computing) [20](#bcp13846-bib-0020){ref-type="ref"} with the Xpose4 package v.4.6.0 [21](#bcp13846-bib-0021){ref-type="ref"}, RStudio [22](#bcp13846-bib-0022){ref-type="ref"} and Pirana v.2.9.6 [23](#bcp13846-bib-0023){ref-type="ref"} were used for data exploration, diagnostics, graphics and automation throughout the modelling process. Measured plasma concentrations below the LLOQ were imputed with half of the LLOQ (Beal\'s M5‐method) [24](#bcp13846-bib-0024){ref-type="ref"}. Several disposition models (e.g. one‐, two‐ and three‐compartment disposition models) and absorption models \[first‐order absorption with and without lag, and transit compartment models with a fixed number of transit compartments (1--15) with k~a~ and k~tr~ assumed equal or estimated separately\] were evaluated [25](#bcp13846-bib-0025){ref-type="ref"}. Relative bioavailability (F) was fixed to unity for the population but with an estimated interindividual variability. An exponential error model was used to describe the interindividual variability in the pharmacokinetic parameters and the residual unknown variability was described by an additive error on the individually predicted logarithmic concentrations (i.e. essentially equivalent to an exponential error on the arithmetic scale).

Effect of both body weight and fat‐free mass were evaluated with allometric scaling on all clearances and volumes parameters with an exponent of 0.75 and 1, respectively [26](#bcp13846-bib-0026){ref-type="ref"}. In addition, the exponents were also estimated. Biologically plausible covariates (e.g. age, sex, body mass index, weight, height and albumin) were tested with a step‐wise covariate approach using a forward selection (*P =* 0.05) and a more stringent backward elimination step (*P =* 0.01) [27](#bcp13846-bib-0027){ref-type="ref"}. For isoniazid, a mixture model was used evaluated to describe the different clearances in patients with slow and fast acetylator status (since the genotype was not known).

Visual inspection of the goodness of fit of observed versus predicted concentration--time profile and the objective function value (OFV), proportional to −2 times the log‐likelihood of data, were used for model discrimination. A reduction in OFV of 3.84 was considered a significant improvement in model fit (*P* \< 0.05) between two nested models, with one degree of freedom difference. The predictive performance of the models was evaluated using visual predictive checks (*n =* 1000). Shrinkage of both η and ε were calculated to determine the reliability of diagnostic plots [28](#bcp13846-bib-0028){ref-type="ref"}. The robustness of the final parameter estimates was determined using bootstrapping by generating 1000 resampled datasets. The *posthoc* individual pharmacokinetic parameter estimates were used to calculate individual C~max~ and exposures (AUC~0--24~).

Dose optimization {#bcp13846-sec-0013}
-----------------

The developed final population pharmacokinetic models were used to evaluate the exposure of isoniazid and rifampicin through stochastic simulations in NONMEM. A total of 1000 individuals were simulated per kg of body weight from 6 to 30 kg for every currently recommended dose regimen and, if necessary, for an improved dose regimen. Steady‐state peak concentrations and exposures were evaluated as a proxy for the efficacy of the different regimens.

Results {#bcp13846-sec-0014}
=======

A total of 41 children completed the study, of whom 27 were on the thrice‐weekly intermittent regimen recommended by RNTCP and 14 were on the daily regimen recommended by the WHO. For isoniazid, there were a total of 290 concentration--time measurements from 39 children, as samples from two children could not be measured due to an LC--MS/MS breakdown on the day of sampling. For rifampicin, there were 284 concentration--time measurements from 39 children, with two children excluded from the modelling process as the concentration--time profile showed an unreasonable delay in absorption of around 2 h, which could have been due to an error in recording sampling time or due to measurement errors. A total of 20 (7%) out of 290 observations and 45 (16%) out of 284 observations were below the LLOQ for isoniazid and rifampicin, respectively. All the observations below LLOQ were part of the elimination phase and almost exclusively trough concentrations for both the drugs.

Pharmacokinetic properties of isoniazid {#bcp13846-sec-0015}
---------------------------------------

Isoniazid concentration--time data were most adequately described by a one‐compartment disposition model. A two‐compartmental disposition model resulted in a significantly improved model fit compared to a one‐compartmental model (∆OFV = −6.8; 2df) but produced a very high interindividual variability on the peripheral volume of distribution and showed a low precision in this parameter estimate (RSE = 66% CV). The absorption phase was best described by a transit compartment model with five fixed transit compartments (*k* ~A~ and *k* ~TR~ were set to be equal since estimating them separately did not improve the model fit). The transit absorption model proved superior to the first order absorption model with lag (∆OFV = −19.2). The addition of relative bioavailability improved the model fit significantly (∆OFV = −16.6).

Body weight added allometrically to clearance and volume parameters improved the model significantly (∆OFV = −37.3). Estimating the exponent of the allometric scaling did not improve the model fit and was therefore not pursued further (∆OFV = −3.2). A mixture model was successfully implemented (∆OFV = −11.9) to identify the two subgroups with different elimination clearances, resulting in an estimated 31% of children having rapid clearance (i.e. fast acetylator status). No other covariates could be retained in the stepwise covariate approach. Primary parameter estimates and secondary parameters derived from the final model are presented in Table [3](#bcp13846-tbl-0003){ref-type="table"}.

###### 

Population pharmacokinetic parameters of isoniazid

  Parameter                                             Population estimates (%RSE)                                   95% CI          %CV for BSV \[%RSE\]   95% CI       Shrinkage (%)
  ----------------------------------------------------- ------------------------------------------------------------- --------------- ---------------------- ------------ ---------------
  **CL** ~**SLOW**~ **/F (l h** ^**--1**^ **)**         2.59 (9.95)                                                   2.12--3.17      ‐                      ‐            ‐
  **CL** ~**FAST**~ **/F (l h** ^**--1**^ **)**         7.79 (7.38)                                                   6.71--9.01      ‐                      ‐            ‐
  **Vc/F (l)**                                          29.7 (7.66)                                                   25.3--34.6      23.4 (14.1)            16.9--30.2   25.4
  **MTT(h)**                                            0.547 (12.6)                                                  0.411--0.695    68.2 (13.9)            49.3--94.3   13.8
  **No. of trans comp**                                 5 fix                                                         ‐               ‐                      ‐            ‐
  **F (%)**                                             100 fix                                                       ‐               41.8 (12.1)            30.1--51.9   23.5
  **RUV**                                               0.0967 (9.79)                                                 0.0639--0.141   ‐                      ‐            29.46
  **Secondary parameters**                                                                                                                                                
  **AUC** ~**(0--24)**~ **(mg × h l** ^**--1**^ **)**   34.04 (23.29--44.23)[a](#bcp13846-note-0007){ref-type="fn"}                                                       
  **C** ~**max**~ **(mg l** ^**--1**^ **)**             5.90 (4.12--7.73)[a](#bcp13846-note-0007){ref-type="fn"}                                                          
  **T** ~**max**~ **(h)**                               1.10 (0.82--1.43)[a](#bcp13846-note-0007){ref-type="fn"}                                                          

Population estimates are given for a typical child weighing 19.4 kg with tuberculosis. CL~FAST~ is the apparent elimination clearance in patients with fast acetylator status (seen in 31% of children) and CL~SLOW~ is the apparent elimination clearance in patients with slow acetylator status (seen in 69% of children), as derived by a mixture model. Vc/F is the apparent volume of distribution of the central compartment. MTT is the mean transit time. No. of trans comp is the number of transit compartments used in the absorption model. F is the relative bioavailabilty. BSV is between subject variability. RSE is relative standard error and is calculated as 100 × (standard deviation/mean). RUV is the residual unexplained variability. C~max~ is the maximum concentration. T~max~ is the time after dose to reach C~max~. AUC is the area under the concentration--time curve from time 0 to 24 h

values are presented as median (interquartile range)

A bootstrapping procedure found the parameter estimates to be reliable with acceptable relative standard errors (Table [3](#bcp13846-tbl-0003){ref-type="table"}). The η shrinkages and ε shrinkage were found to be low (Table [3](#bcp13846-tbl-0003){ref-type="table"}). Goodness‐of‐fit plots and the visual predictive check indicated that the model described the observed data well and had good predictive performance (Figure [1](#bcp13846-fig-0001){ref-type="fig"}).

![Visual predictive checks of the final models. (A) Prediction corrected visual predictive check of the final population pharmacokinetic model of isoniazid. (B) Visual predictive check of the final population pharmacokinetic model of rifampicin. Both A and B are based on 1000 stochastic simulations. Open circles represent the observations, and solid lines represent 50^th^ percentile while the dotted lines represent the 5^th^ and 95^th^ percentiles of the observed data. The shaded areas represent the 95% confidence intervals around the simulated 5th, 50th, and 95th percentiles. The horizontal dotted line represents the lower limit of quantification](BCP-85-644-g001){#bcp13846-fig-0001}

Pharmacokinetic properties of rifampicin {#bcp13846-sec-0016}
----------------------------------------

The pharmacokinetic properties of rifampicin were best described by a one‐compartment disposition model. A two‐compartmental disposition model resulted in a significantly improved model fit compared to a one‐compartmental model (∆OFV = −34.0). However, this resulted in a negligible improvement in visual predictive check and goodness of fit diagnostics. The absorption phase was best described by a transit compartment model with nine transit compartments (∆OFV = −156). *k* ~A~ and *k* ~TR~ were set to be equal, since estimating them separately did not improve the model fit. The addition of relative bioavailability improved the model fit significantly (∆OFV = −48.2). Body weight was added allometrically to clearance and volume parameters resulted in a significant improvement in model fit (∆OFV = −7.3). Estimating the allometric scaling did not improve the model fit further (∆OFV =3.4). The autoinduction of metabolizing enzymes could not be estimated since only steady‐state samples were collected. No other covariates could be retained in the stepwise covariate approach. Primary parameter estimates and secondary parameters derived from the final model are presented in Table [4](#bcp13846-tbl-0004){ref-type="table"}.

###### 

Population pharmacokinetic parameters of rifampicin

  Rifampicin                                            Population Estimates (%RSE)                                   95% CI         %CV for BSV \[%RSE\]   95% CI       Shrinkage (%)
  ----------------------------------------------------- ------------------------------------------------------------- -------------- ---------------------- ------------ ---------------
  **CL/F (l h** ^**--1**^ **)**                         8.11 (10.9)                                                   6.62--10.1     ‐                      ‐            ‐
  **Vc/F (l)**                                          44.7 (14.6)                                                   34.2--59.5     42 (12.6)              31.1--53.9   3.40
  **MTT (h)**                                           0.932 (9.92)                                                  0.743--1.12    52.2 (12.7)            39.7--68.0   5.06
  **No. of trans comp**                                 9 fix                                                         ‐              ‐                      ‐            ‐
  **F (%)**                                             100 fix                                                       ‐              68.0 (16.6)            40.0--95.6   10.71
  **RUV**                                               0.271 (8.96)                                                  0.191--0.379   ‐                      ‐            19.61
  **Secondary parameters**                                                                                                                                               
  **AUC** ~**(0--24)**~ **(mg × h l** ^**--1**^ **)**   25.19 (15.69--34.85)[a](#bcp13846-note-0009){ref-type="fn"}                                                      
  **C** ~**max**~ **(mg l** ^**--1**^ **)**             4.73 (2.74--6.23)[a](#bcp13846-note-0009){ref-type="fn"}                                                         
  **T** ~**max**~ **(h)**                               1.59 (1.31--2.12)[a](#bcp13846-note-0009){ref-type="fn"}                                                         

Population estimates are given for a typical child weighing 19.4 kg with tuberculosis. CL/F is the apparent elimination clearance, Vc/F is the apparent volume of distribution of the central compartment, MTT is the mean transit time. No. of trans comp is the number of transit compartments used in the absorption model. F is the relative bioavailabilty. BSV is between subject variability. RSE is relative standard error and is calculated as 100 × (standard deviation/mean). RUV is the residual unexplained variability. C~max~ is the maximum concentration. T~max~ is the time after dose to reach C~max~. AUC is the area under the concentration--time curve from time 0 to 24 h

values are presented as median (interquartile range)

A bootstrapping procedure found the parameter estimates to be reliable with acceptable relative standard errors (Table [4](#bcp13846-tbl-0004){ref-type="table"}). The η shrinkages and ε shrinkage were found to be low (Table [4](#bcp13846-tbl-0004){ref-type="table"}). Goodness‐of‐fit plots and the visual predictive check indicated that the model described the observed data well and had good predictive performance (Figure [1](#bcp13846-fig-0001){ref-type="fig"}).

Dose optimization {#bcp13846-sec-0017}
-----------------

The final population pharmacokinetic models were used to simulate the isoniazid and rifampicin concentration--time profiles for a population of children weighing 6--30 kg (*n* = 1000 at each bodyweight). Drug exposures (i.e. C~max~ and AUC~0--24~) after administration of the investigated regimens were derived from the *posthoc* estimates from NONMEM. The percentage of children obtaining the target concentration with the different dosage regimens is summarized in Table [5](#bcp13846-tbl-0005){ref-type="table"}.

###### 

Target attainment in a simulated population with adequate exposure with various regimens

  Drug                                Target                   Percentage of simulated population who attained target                 
  ----------------------------------- ------------------------ -------------------------------------------------------- ------ ------ ------
  **Isoniazid**                                                                                                                       
  ***Fast acetylators***              C~max~ \> 6 μg ml^--1^   41.6                                                     47.6          
  C~max~ \> 3 μg ml^--1^              88.6                     90.6                                                     84.9          
  AUC~0--24~ \> 10.5 μg × h ml^--1^   95.9                     97.1                                                     94.1          
  ***Slow acetylators***              C~max~ \> 6 μg ml^--1^   60.6                                                     73.1          
  C~max~ \> 3 μg ml^--1^              95.9                     98.6                                                     94.4          
  AUC~0--24~ \> 10.5 μg × h ml^--1^   99.9                     100                                                      99.9          
  **Rifampicin**                                                                                                                      
                                      C~max~ \> 8 μg ml^--1^   15.1                                                     17.8   28.8   74.2
                                      C~max~ \< 4 μg ml^--1^   53.7                                                     48.9   34.3   5.2

Isoniazid: C~max~ \> 6 μg ml^--1^ and \> 3 μg ml^--1^ are considered as therapeutic targets in thrice‐daily and daily therapy respectively. An AUC~0--24~ \> 10.5 μg × h ml^--1^ is considered adequate in terms of early bactericidal activity

Rifampicin: C~max~ \> 8 μg ml^--1^ is considered as therapeutic target and \< 4 μg ml^--1^ is considered very low

All regimens are as described in Table [1](#bcp13846-tbl-0001){ref-type="table"}. Regimen 3 is only daily therapy. Regimen 4 was simulated only for rifampicin as exposure for isoniazid with present regimen was deemed adequate

For isoniazid, when given as Regimen 2 (current regimen), the simulations suggest that only 59% of all patients had a C~max~ \> 6 μg ml^--1^ when given as the thrice weekly regimen while 96% had a C~max~ \> 3 μg ml^--1^ when given as the daily regimen. However, 99.9% of all the patients had an AUC~0--24~ \> 10.5 μg × h ml^--1^ for both daily and thrice‐weekly regimens (Figure [2](#bcp13846-fig-0002){ref-type="fig"}), which should be considered adequate treatment. The simulated concentrations with the planned Regimen 3 resulted in a C~max~ \> 3 μg ml^--1^ in about 88% of patients and simulated AUC~0--24~ \> 10.5 μg × h ml^--1^ in 96% of all patients. The percentage of patients attaining the target in each of the acetylator statuses is elaborated in Table [5](#bcp13846-tbl-0005){ref-type="table"}. Fast acetylators are generally at higher risk of underexposure, but 85% of the patients had the required C~max~ \> 3 μg ml^--1^ and 94% of patients had the required AUC \> 10.5 μg × h ml^--1^ with regimen 3. Thus, there was no need to improve the dosing regimen further for isoniazid.

![Stochastic simulated median, 25^th^ and 75^th^ percentiles of (A) maximum concentrations (C~max~) and (B) area under the concentration--time curve (AUC) values after dosing with isoniazid according to national programme post‐2012 (regimen 2). The dotted line in figure A represents the required therapeutically effective C~max~ of 6 μg ml^--1^ in an intermittent regimen, while the dashed line represents the therapeutically effective concentration of 3 μg ml^--1^ in the daily regimen. The solid line in figure B represents the AUC of 10.52 μg × h ml^--1^, which is considered as therapeutically effective AUC](BCP-85-644-g002){#bcp13846-fig-0002}

For rifampicin, all the regimens were found to show a low exposure (C~max~) compared to the therapeutic level (Figure [3](#bcp13846-fig-0003){ref-type="fig"}). Even when simulated with the planned regimen 3, only 29% of patients had a C~max~ \> 8 μg ml^--1^ while 34% had a C~max~ \< 4 μg ml^--1^. To improve the treatment with rifampicin, multiple novel regimens were tried using available formulations and a new and improved dose regimen was derived, as presented in Table [1](#bcp13846-tbl-0001){ref-type="table"}. Using this regimen, 74% of patients attained a C~max~ \> 8 μg ml^--1^ with an average dose of 35 mg kg^--1^ (Figure [4](#bcp13846-fig-0004){ref-type="fig"}).

![Stochastic simulated median, 25^th^ and 75^th^ percentiles of maximum concentration values after dosing with rifampicin according to national programme post‐2012 (regimen 2). The solid line represents the required therapeutically effective concentration of 8 μg ml^--1^, while the dotted line represents a concentration of 4 μg ml^--1^, below which is considered very low](BCP-85-644-g003){#bcp13846-fig-0003}

![Stochastic simulated median, 25^th^ and 75^th^ percentiles of maximum concentration values after the derived optimal dose regimen for rifampicin (35 mg kg^--1^). The band comprising of 6--11‐kg children will use a suspension available commercially. Other weight bands will use regular capsules. The solid line indicates the required therapeutically effective concentration of 8 μg ml^--1^, while the dotted line represents a concentration of 4 μg ml^--1^, below which is considered very low](BCP-85-644-g004){#bcp13846-fig-0004}

Discussion {#bcp13846-sec-0018}
==========

This study developed a population pharmacokinetic models for the antituberculosis drugs isoniazid and rifampicin. The developed model was used to evaluate the current dosing regimens and to derive a novel regimen that would reach the recommended therapeutic target concentration.

Isoniazid pharmacokinetics were described by a one‐compartment disposition model. Apparent elimination clearances and apparent volume of distribution of the central compartment reported earlier [7](#bcp13846-bib-0007){ref-type="ref"}, [29](#bcp13846-bib-0029){ref-type="ref"}, differs slightly compared to the values estimated with the present model but this difference could potentially be attributed to ethnicity, differences in age distribution of the children, and the different methods of classification of acetylator status. In contrast to adults, data on isoniazid elimination clearance in children are scarce. The median simulated AUC~0--8~ obtained in this study was 25.53 \[interquartile range (IQR) 18.22--31.76\], which is much lower compared to the median AUC~0--8~ of 41.1 (IQR 33.0--59.9) obtained in an adult population in a study from India [30](#bcp13846-bib-0030){ref-type="ref"}. One of the limitations of the present study is that the acetylator status of the children is not known. If it was known, it could have been included as a categorical covariate in the present model. However, this was handled by introducing the mixture model, which adequately described the population size of the two groups. In the present model, 30.8% were found to be fast acetylators and 69.2% to be slow acetylators. This finding is supported by results from another study on the phenotype of acetylation status in India where 66% were found to be slow acetylators [31](#bcp13846-bib-0031){ref-type="ref"}. An interesting observation with the model was that the maximum concentration of isoniazid was reached at 1.1 h, with an IQR of 0.8--1.4 h. This information could help in designing future studies in children as this is in contrast with most studies, which assumed that maximum concentrations would be reached at 2 h.

Rifampicin pharmacokinetics were described by a one‐compartment disposition model. Although the two‐compartment disposition model provided a better OFV did not improve in terms of VPC. Moreover, the two‐compartment model also produced an implausible terminal elimination half‐life of 1220 h compared to published literature (2--3 h). The children in the present study, although densely sampled, were only sampled for a period of 6 h to minimize inconvenience for them, which a prolonged sampling schedule would have caused. This lack of late samples might limit the information about the elimination phase, which could have resulted in this effect. Most published literature also describe rifampicin by a one‐compartment disposition model [7](#bcp13846-bib-0007){ref-type="ref"}, [9](#bcp13846-bib-0009){ref-type="ref"}. Thus, a one‐compartment model was carried forward in the modelling process. The hepatic clearance of rifampicin nearly doubles over the course of the therapy due to auto‐induction and reached a steady state after 22--40 days [9](#bcp13846-bib-0009){ref-type="ref"}, [32](#bcp13846-bib-0032){ref-type="ref"}. Since all the children in this study had around 60 days of rifampicin therapy before pharmacokinetic samples were collected, the clearance could be assumed to remain constant over time and an auto‐induction model was not used. The parameter estimates obtained from the model developed was similar to that reported earlier [7](#bcp13846-bib-0007){ref-type="ref"}, [29](#bcp13846-bib-0029){ref-type="ref"}.

Simulation were performed to evaluate dose regimens for the different drugs. For isoniazid, 94% of all children on daily therapy with the present regimen had adequate simulated C~max~. Moreover, about 99% of all children had simulated AUC~0--24~ \> 10.5 μg h ml^--1^ irrespective of the frequency of dosing. After simulations with Regimen 3 (daily therapy with a slightly lower mean per kg dose for isoniazid), adequate C~max~ and AUC were still obtained in most of the children. This was true even when simulated with fast acetylators alone. Therefore, it was decided that further optimization of the dose regimen for isoniazid was not necessary. Even if the dosing for children aged 2--16 years seems to be adequate, this cannot be assumed to be true for younger children (age \<2 years) as enzyme maturation needs to be taken into account for this group [33](#bcp13846-bib-0033){ref-type="ref"}.

Exposure to rifampicin was generally very low in all regimens and only about 17.8% of the children had a high enough exposure with the widely used Regimen 2. Attaining the recommended C~max~ is important in rifampicin therapy to be able to cure the disease as its long postantibiotic effect is directly dependent on the peak concentration [34](#bcp13846-bib-0034){ref-type="ref"}, [35](#bcp13846-bib-0035){ref-type="ref"}. The simulations performed showed that the WHO‐recommended FDC‐based regimen (Regimen 3, daily therapy with a slightly higher mean per kg dose for rifampicin) was better than the previous regimens, but with only 28.8% of the children getting adequate exposure. Therefore, simulations of a new optimal multiple dose regimen were investigated. Based on the simulations a dose of 35 mg kg^--1^ was found to result in adequate exposure in most patients receiving adequate treatment (74.2% above 8 μg ml^--1^ and only 5.15% below 4 μg ml^--1^). Although this is an increased dose compared to that recommended by WHO, recent clinical trials in adults using higher doses of up to 35 mg kg^--1^ per kg of rifampicin have been shown to be safe when given daily [36](#bcp13846-bib-0036){ref-type="ref"}, [37](#bcp13846-bib-0037){ref-type="ref"}.

The dosing of rifampicin has been debated for a long time. The current adult dose of 600 mg was recommended in the 1970s based on the perception that toxicity was dose‐related, and due to the high cost of rifampicin at that time [38](#bcp13846-bib-0038){ref-type="ref"}. With the current evidence of an adequate safety profile with higher doses (35 mg kg^--1^) and lower manufacturing costs, dose revisions should be considered [36](#bcp13846-bib-0036){ref-type="ref"}, [37](#bcp13846-bib-0037){ref-type="ref"}. To our knowledge, high‐dose therapy has not yet been investigated in children. However, it has been shown that adverse events are generally lower in children compared to adults [39](#bcp13846-bib-0039){ref-type="ref"}. The flu‐like symptoms initially considered to be related to high doses are now believed to be due to the intermittent nature of past therapies [40](#bcp13846-bib-0040){ref-type="ref"}. An ideal strategy would be to use regimens prescribed in current guidelines to initiate therapy and thereafter to individualize doses based on therapeutic drug monitoring. However, this might not be feasible in resource‐limited settings. therefore, the practical approach would be to initiate therapy with higher doses of rifampicin, as has been simulated in the present study (approximately 35 mg kg^--1^). Similar advice has been given recently by authors of other studies [29](#bcp13846-bib-0029){ref-type="ref"}, [41](#bcp13846-bib-0041){ref-type="ref"}. Most current information on drug dosing is based on *in vivo* experiments and phase I trials without a clear concentration‐clinical efficacy relationship [12](#bcp13846-bib-0012){ref-type="ref"}. Therefore, additional studies with both pharmacokinetic and pharmacodynamic data would be beneficial.

In conclusion, this study characterized the pharmacokinetic properties of isoniazid and rifampicin using nonlinear mixed‐effects modelling. The current dosing schedules were adequate for isoniazid, but modelling and simulation suggested that rifampicin was under‐dosed. The developed models were used to derive a new optimized dose regimen in order to attain recommended therapeutic concentrations and improve the treatment of tuberculosis in children. Further studies are needed to investigate the dose--effect relationship of antituberculous drugs in children, especially with higher doses of rifampicin.
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